Echoes of ancient wisdom and synergistic strategies invigorate the fight against liver fibrosis

Abstract

The persistent clinical impasse in the development of approved antifibrotic therapies underscores the limitations of reductionist magic bullet strategies against the networks driving liver fibrosis. In this opinion review, we explore recent advances in botanical synergy, utilizing the Crocus sativus-Calculus bovis medicinal pair as a paradigmatic model to validate a systems pharmacology approach that transcends empirical tradition. Beyond the concurrent modulation of the p38 MAPK and transforming growth factor-β/Smad axes, we highlight the capacity of the combinatorial interventions to exert pleiotropic effects through microbiome crosstalk via the gut-liver axis, immunometabolic reprogramming of macrophages, and epigenetic modulation. To translate the botanical intelligence into global viable pharmaceutical assets, future research must leverage artificial intelligence and spatial multi-omics to decode these dynamic pharmacological networks. Furthermore, we argue that development should pivot from static chemical standardization to bioactivity-linked quality markers to ensure bioequivalence, particularly when artificial substitutes are utilized. Successful clinical translation also demands a strategic evolution toward precision medicine, integrating real-world evidence, stratification biomarkers, and noninvasive surrogate endpoints to identify patient endotypes. Ultimately, this opinion review serves as a prototype for network medicine, suggesting that fusing the combined logic of ancient pharmacopeia with the precision of modern molecular biology constitutes a transformative blueprint for conquering multifactorial diseases.

Key Words: Liver fibrosis; Systems pharmacology; Network medicine; Bioactivity-based quality control; Drug synergism

Core Tip: The failure of reductionist magic bullet therapies in liver fibrosis necessitates a shift toward systems pharmacology and network regulation. Serving as a prime example of this paradigm, the Crocus sativus-Calculus bovis pair validates combinatorial strategies that simultaneously modulate the p38 MAPK and transforming growth factor-β/Smad axes to collapse the fibrogenic network. Clinical success depends on evolving from chemical standardization to bioactivity-linked quality control and adopting precision medicine to stratify patient endotypes.

INTRODUCTION

Liver fibrosis, a relentless scarring process representing the final common pathway of chronic hepatic injury, represents one of the most formidable challenges in modern hepatology. It is a silent epidemic, progressing millions of patients toward cirrhosis, hepatocellular carcinoma, and liver failure each year. However, a glaring paradox defines our current scientific landscape. While we live in a golden age of molecular elucidation, possessing a deep understanding of hepatic stellate cell activation and the cytokine networks driving extracellular matrix deposition, clinical translation remains elusive[1-3]. We have mapped the genome, cataloged the transcriptome, and dissected the proteome of the fibrotic liver[4,5]. Despite this wealth of data, the clinical armamentarium remains barren. To date, no specific antifibrotic therapy has successfully navigated the regulatory gauntlet to secure approval from the United States Food and Drug Administration or the European Medicines Agency. The history of antifibrotic drug development is littered with high-profile failures, such as simtuzumab and selonsertib[6]. This persistent clinical impasse forces an epistemic reckoning regarding our fundamental approach and suggests that the reductionist reliance on high-affinity, single-target magic bullets may be flawed when applied to a disease with as many overlapping etiologies as liver fibrosis.

SYNERGISTIC MECHANISMS AND NETWORK LOGIC

Dissecting the synergistic mechanics of the classic Tibetan medicinal pair Crocus sativus (C. sativus) and Calculus bovis (C. bovis) assumes a significance that transcends its immediate findings. This research documents the efficacy of this combination and highlights a blueprint for a systems-based therapeutic strategy. The fibrogenic response of the liver is not a linear pathway but a dense, scale-free network protected by complex compensatory feedback loops. The inhibition of a single node, such as ASK1, LOXL2, or CCR2, triggers a hydra effect in which the biological system dynamically reroutes signaling through alternative pathways to maintain the fibrogenic phenotype[7-11]. The failure of monotherapies in late-stage clinical trials is likely a manifestation of this biological redundancy. Therefore, the multicomponent, multitarget logic embedded in traditional medicine provides a rational alternative, a combinatorial assault[12] that gently perturbs multiple nodes of the network simultaneously, collapsing the disease state without triggering the toxic compensatory mechanisms often seen with high-dose single-target ablation (Table 1).

Table 1 Epistemic evolution in antifibrotic drug discovery.

Feature	Reductionist paradigm (current)	Systems pharmacology paradigm (proposed)	Mechanistic rationale
Therapeutic philosophy	Linear monotargeting: High-affinity blockade of isolated molecular targets	Network perturbation: Combinatorial modulation of topological hubs	Topological vulnerability: Fibrotic networks are scale-free; simultaneous multi-node perturbation collapses topology
System response	Hydra effect (compensatory rerouting): Dynamic activation of alternative signaling pathways to sustain fibrogenesis	Synergistic attenuation: Concurrent, low-grade dampening of parallel pathways prevents feedback loop activation	Biological robustness: Monotherapy triggers homeostatic compensation; combinatorial logic disrupts system
Safety profile	High-dose toxicity: Requires high receptor occupancy, risking physiological homeostasis disruption	Improved therapeutic index: Efficacy achieved via additive/synergistic interactions at sub-toxic concentrations	Pharmacodynamic synergy: Constituents exert entourage effects
Developmental focus	Affinity-based optimization: IC50 and molecular selectivity	Phenotype-driven efficacy: Maximizing phenotypic reversion	Functional bioequivalence: Shifts validation metrics from chemical purity to bioactivity linked network modulation

In the published study, the emerging discipline of network pharmacology was coupled with in vivo validation to demonstrate that the C. sativus-C. bovis combination exerts an antifibrotic effect in a carbon tetrachloride-induced rat model of liver fibrosis[13]. The synergy is traced to the simultaneous modulation of the p38 MAPK axis and the canonical transforming growth factor-β (TGF-β)/Smad pathway[14-18]. TGF-β1 is the master regulator of fibrogenesis, though direct blockade of TGF-β has historically been plagued by systemic toxicity and oncogenic risks[19,20]. These findings suggest that this pair of naturally occurring substances acts as a network regulator, dampening the downstream signaling amplitude of TGF-β via crosstalk with the MAPK pathway rather than completely blocking the receptor. Furthermore, the active constituents likely address the multifactorial nature of liver injury: The crocin/crocetin from C. sativus provides potent antioxidant and anti-inflammatory stabilization[21-23], while the bile acids and bilirubin from C. bovis modulate cholestasis and cytoprotection[24-26]. This is a classic example of pharmacodynamic synergy in which the therapeutic index of the whole exceeds the sum of its components.

HARNESSING MICROBIAL CROSSTALK AND THE GUT-LIVER AXIS

Beyond direct hepatic signaling, the gut-liver axis emerges as a pivotal frontier in understanding the systemic efficacy of medicinal pairs[27-30]. Bile acids from C. bovis inherently function as potent signaling molecules that regulate intestinal permeability and modulate the enteric microbiome via farnesoid X receptor activation[31,32]. Concurrently, the antioxidant properties of C. sativus alleviate intestinal oxidative stress, thereby reducing the translocation of fibrogenic endotoxins into the portal circulation[33-35]. Modulating the microbiome provides an upstream intervention strategy that prevents the initial activation of hepatic stellate cells[36,37]. Investigating the reciprocal interactions between botanical metabolites and gut microbiota will unveil a novel dimension of therapeutic synergy, positioning microbiome targeted interventions as a cornerstone of future antifibrotic regimens. Emerging evidence indicates that the therapeutic potential of botanical formulations extends deeply into microbial biotransformation. The resident flora actively metabolizes complex phytocompounds into highly bioavailable secondary metabolites, effectively acting as an endogenous bioreactor. For instance, the microbial cleavage of crocin yields crocetin, a compound with superior membrane permeability and enhanced antifibrotic capacity[38-41]. Concurrently, the modulation of the intestinal microbial architecture by the medicinal pair restores the integrity of tight junction proteins, including zonula occludens 1 and occludin[42,43]. Restoring the mucosal barrier halts the influx of pathogen associated molecular patterns into the hepatic portal system, thereby silencing the Toll-like receptor 4 signaling cascade in Kupffer cells[44,45]. By dampening the primary inflammatory trigger at the intestinal source, the combinatorial strategy fundamentally alters the hepatic microenvironment. Expanding future research to include multiomics profiling of the microbiome and the corresponding metabolome will provide an understanding of interorgan pharmacological networks, refining precision dosing strategies for liver pathologies.

MODULATING IMMUNOMETABOLISM AND MACROPHAGE POLARIZATION

The resolution of liver fibrosis depends on the dynamic plasticity of the hepatic immune microenvironment. Hepatic macrophages, encompassing resident Kupffer cells and recruited monocyte-derived populations, dictate the balance between extracellular matrix deposition and degradation. Modern investigations reveal that traditional medicinal pairs excel at orchestrating macrophage polarization, effectively shifting the local immune milieu from a proinflammatory state to a restorative phenotype. The phenotypic transition is fundamentally linked to immunometabolism, wherein botanical agents reprogram the metabolic pathways of immune cells, steering them away from aerobic glycolysis toward oxidative phosphorylation[46,47]. Modulating the metabolic state of macrophages curtails the secretion of profibrotic cytokines while enhancing the production of matrix metalloproteinases necessary for scar resolution[48,49]. Deciphering the immunometabolic regulatory networks targeted by the formulation will provide crucial insights into the tissue repair mechanisms, establishing a framework for immune-targeted antifibrotic therapies.

TARGETING EPIGENETIC REPROGRAMMING IN FIBROGENESIS

Beyond signal transduction, the epigenetic regulation of hepatic stellate cells represents a dimension of botanical pharmacology. The transdifferentiation of quiescent stellate cells into myofibroblasts is driven by alterations in chromatin accessibility, DNA methylation, and histone modification. Emerging research highlights that multicomponent botanical formulations frequently function as potent epigenetic modulators. Active metabolites derived from the medicinal pair possess the capacity to regulate histone deacetylase activity[50,51] and modulate the expression profiles of profibrotic microRNAs[52]. By resetting the epigenetic landscape, the combinatorial therapy facilitates the reversion of activated stellate cells to a quiescent phenotype or induces targeted apoptosis. The epigenetic resetting mechanism provides a compelling explanation for the sustained therapeutic memory often observed with traditional remedies, wherein clinical benefits persist long after the cessation of treatment. Integrating epigenomic profiling into future pharmacological evaluations will uncover the regulatory layers governing botanical efficacy.

EMERGING TECHNOLOGIES AND SYSTEMIC MODULATION

Incorporating artificial intelligence and spatial transcriptomics provides a transformative methodology to decode the pharmacological networks of botanical formulations. Conventional network pharmacology frequently relies on static databases, which may fail to capture the dynamic temporal alterations in fibrotic microenvironments. Advanced machine learning algorithms, when integrated with single-cell RNA sequencing and metabolomics, can accurately exhibit the cellular targets of crocin and bilirubin within the hepatic niche. By mapping the precise molecular trajectories of active compounds, researchers can transition from theoretical network predictions to empirical, high-resolution pharmacological mapping. The deployment of deep learning models will ultimately accelerate the identification of synergistic nodes, ensuring that combinatorial therapies are optimized for maximum antifibrotic efficacy.

CHALLENGES IN STANDARDIZATION AND CLINICAL TRANSLATION

However, acknowledging the scientific validity of this approach is only the first step. Translating an empirical formula into a global pharmaceutical asset requires navigating a minefield of challenges that lies at the intersection of botany, chemistry, and regulatory science (Table 2). The most immediate hurdle is the Achilles’ heel of standardization. The study utilizes artificial C. bovis, a pragmatic response to the scarcity, ethical concerns, and prohibitive cost of natural ox gallstones. However, this substitution invites a question regarding bioequivalence.

Table 2 Strategic roadmap for modernizing botanical therapeutics in liver fibrosis.

Developmental phase	Current bottleneck/challenge	Strategic evolution	Key technologies
CMC & standardization	Static chemical markers. Quality control based on 1-2 abundant compounds. Fails to capture entourage effects or bioequivalence of substitutes	Bioactivity-linked markers. Correlate chemical fingerprints directly with phenotypic bioactivity. Standardize biological output, not just chemical input	High-resolution metabolomics. Phenotypic screening
Formulation strategy	Raw extracts vs pure compound. Extracts lack reproducibility. Pure compounds lose matrix synergy	Enriched fractions. Chemically defined active fractions. Retains synergistic matrix; removes inert/toxic loads	Fractionation chemistry. PK/PD modeling
Patient stratification	All-comers trial design. Treats fibrosis as a monolithic entity. Ignores heterogeneity of MASH	Precision endotyping. Identify subgroups driven by oxidative stress/inflammation. Match patient endotype to drug mechanism	Genomic profiling. Inflammatory biomarkers
Clinical endpoints	Invasive liver biopsy. Sampling error and variability. High barrier to patient recruitment	Non-invasive surrogate endpoints. Dynamic markers of fibrogenesis. Enables rapid, ethical efficacy assessment	MR/shear wave elastography. Liquid biopsy

CMC: Chemical, manufacturing, and controls; PK/PD: Pharmacokinetic/pharmacodynamic; MASH: Metabolic dysfunction-associated steatohepatitis; MR: Magnetic resonance.

Natural products function as chemical ecosystems. Natural C. bovis contains a spectrum of trace elements and microbiome-derived metabolites that are often absent in artificial formulations, which are typically simple mixtures of bilirubin and bile acids. It is unclear whether these minor components contribute to an entourage effect that enhances bioavailability or efficacy. We must move beyond archaic quality control standards based on one or two marker compounds. The modernization of this medicinal pair demands the application of quality markers and high-resolution metabolomics to establish a comprehensive chemical fingerprint that directly correlates batch-to-batch variability with bioactivity in standardized, phenotypic cell-based assays. The biological output, not just the chemical input, should be standardized.

Furthermore, the developmental trajectory of the combinations poses a strategic dilemma. The goal may be a standardized botanical drug product or the isolation and reconstitution of the core synergistic molecules into a novel fixed-dose combination. The latter approach aligns more seamlessly with the precision medicine paradigm and Western regulatory frameworks, allowing for precise pharmacokinetic modeling and dosing. However, the reductionist impulse to purify strips away the very matrix that confers safety and synergy. A fraction-based approach, in which active fractions are enriched while inert or toxic matrix components are removed, may represent the optimal middle ground. This strategy creates a modern therapeutic agent that is chemically defined enough for regulatory confidence, yet biologically complex enough to maintain network-modulating efficacy.

Looking toward the last mile of clinical translation, the challenges are equally daunting. Yet, precedent exists demonstrating that these translational and regulatory hurdles can be successfully overcome by botanical formulations. For instance, in a retrospective real-world study of patients with chronic hepatitis B, the median survival time of cirrhotic patients treated with the Fuzheng Huayu capsule reached 351.6 weeks, significantly higher than the 112.1 weeks observed in non-users[53], demonstrating a statistically significant improvement in the 5-year survival rate. Of even greater international significance, Fuzheng Huayu became the first antifibrotic traditional Chinese medicine to enter phase 2 clinical trials in the United States[54]. In a multicenter, placebo-controlled study involving patients with chronic hepatitis C, it successfully demonstrated both efficacy in suppressing fibrosis progression and an excellent safety profile[55].

While these successes in viral hepatitis provide a powerful proof-of-concept for botanical antifibrotics, the landscape of liver disease is shifting tectonically from viral hepatitis to metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASH)[56]. The heterogeneity of the population of patients with MASH is driven by diverse genetic polymorphisms (such as PNPLA3 and TM6SF2) and metabolic comorbidities[57-60]. A one-size-fits-all clinical trial design is destined to fail. If this C. sativus-C. bovis pair is to succeed where others have failed, future clinical investigations must employ stratification biomarkers to identify patient subgroups whose disease is specifically driven by the inflammatory and oxidative pathways targeted by these agents. Rather than addressing fibrosis in a nonspecific manner, therapeutic strategies should be directed toward the patient’s defined molecular endotype.

Moreover, the reliance on invasive liver biopsy as the gold standard for clinical endpoints is an unsustainable bottleneck[61,62]. The variability in sampling and interobserver interpretation has hindered the validation of many promising drugs. The field urgently awaits the validation of noninvasive surrogate endpoints, such as magnetic resonance elastography and circulating biomarkers like PRO-C3. Unlike static fibrosis staging, these tools can capture the dynamic changes in fibrogenesis rather than just static fibrosis stages[63,64]. The medicinal pair could serve as an ideal candidate for umbrella trials or adaptive trial designs that integrate these novel biomarkers, allowing for a more rapid and ethical assessment of efficacy.

NAVIGATING CLINICAL COMPLEXITIES AND REAL-WORLD INTEGRATION

Transitioning from controlled laboratory environments to heterogeneous clinical settings requires a paradigm shift in trial methodology. The historical human exposure to traditional botanical pairs provides a unique advantage that randomized controlled trials often fail to capture adequately. Embracing real-world evidence and pragmatic clinical trials provides a vital bridge between centuries of empirical application and contemporary evidence-based medicine. By systematically analyzing electronic health records and patient-reported outcomes, clinicians can identify phenotypic responders within broad patient populations. The strategy not only accelerates the validation process but also captures the long-term safety profiles and subtle quality-of-life improvements that are frequently missed in short-term, highly restrictive clinical protocols. Integrating real-world data ensures that the evaluation of botanical networks reflects actual clinical practice rather than an artificial, idealized cohort.

Furthermore, the clinical deployment of multicomponent therapies should account for the reality of polypharmacy in modern hepatology. Patients presenting with metabolic dysfunction-associated steatohepatitis invariably manage multiple comorbidities, necessitating the concurrent use of antihypertensives, hypoglycemic agents, and lipid-lowering medications. Introducing a botanical matrix into a crowded pharmacological landscape raises valid concerns regarding cytochrome P450-mediated drug interactions. However, the scenario also presents a therapeutic opportunity. The pleiotropic effects of the medicinal pair could potentially mitigate the hepatotoxic side effects of conventional metabolic drugs or act synergistically to lower the required dosages of synthetic agents. Rigorous pharmacokinetic profiling in the presence of standard-of-care regimens is imperative. Addressing the interaction dynamics will ultimately transform botanical formulations from marginalized alternative options into fully integrated, evidence-based adjunctive therapies.

CONCLUSION

Crucially, the clinical realization of this paradigm requires a departure from all-comers trials. Future studies should integrate noninvasive surrogate endpoints (e.g., elastography and circulating collagen biomarkers) to rapidly assess the therapeutic response. Furthermore, adopting adaptive trial designs that stratify patients based on their metabolic and inflammatory endotypes will be essential to identify the subgroups most responsive to the C. sativus-C. bovis intervention, thereby bridging the gap between ancient pharmacopeia and modern evidence-based medicine.